The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Update on islet cell transplantation
Abstract
Purpose of review Chronic diabetes-related complications continue to exert a rapidly growing and unsustainable pressure on healthcare systems worldwide. In type 1 diabetes, glycemic control is particularly challenging, as intensive management substantially increase the risk of severe hypoglycemic episodes. Alternative approaches to address this issue are required. Islet cell transplantation offers the best approach to reduce hypoglycemic risks and glycemic lability, while providing optimal glycemic control. Although ongoing efforts have improved clinical outcomes, the constraints in tissue sources and the need for chronic immunosuppression limit the application of islet cell transplantation as a curative therapy for diabetes. This review provides an update on islet cell transplantation, focusing on recent clinical experience, ongoing research, and future challenges. Recent findings Current evidence demonstrates advances in terms of long-term glycemic control, improved insulin independence rates, and novel approaches to eliminate chronic immunosuppression requirements after islet cell transplantation. Advances in stem cell-based therapies provide a promising path towards truly personalized regenerative therapies, solving both tissue supply shortage and the need for lifelong immunosuppression, enabling widespread use of this potentially curative treatment. However, as these therapies enter the clinical realm, regional access variability and ethical questions regarding commercia…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Subsequent transplantation studies continued to show improved patient outcomes, with islet transplantation approaching the success of whole pancreas transplantation without the corresponding surgical risk.18–23”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [23]
In the citing paper
“Advances in islet isolation methodologies, immunotherapies, and transplantation techniques have improved islet transplantation outcomes in recent years, improving 5-year insulin independence rates to 50-80%.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [23]
Citations
Cites
Kroon, E., Martinson, L. A., Kadoya, K., Bang, A. G., Kelly, O. G., Eliazer, S., Young, H., Richardson, M., Smart, N. G., Cunningham, J., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1393 · Cited by 1,843 · cited 1×
“All rights rese concept’, whereas hESC-derived islets attest to a well described pathway to differentiate stem cells into islets [30].”
BackgroundType 1 diabetes immunotherapy using polyclonal regulatory T cells
Bluestone, J. A., Buckner, J. H., Fitch, M., Gitelman, S. E., Gupta, S., Hellerstein, M. K., Herold, K. C., Lares, A., Lee, M. R., Li, K., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad4134 · Cited by 1,033
Deuse, T., Hu, X., Gravina, A., Wang, D., Tediashvili, G., De, C., Thayer, W. O., Wahl, A., Garcia, J. V., Reichenspurner, H., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0016-3 · Cited by 758
Generation of hypoimmunogenic human pluripotent stem cells
Han, X., Wang, M., Duan, S., Franco, P. J., Kenty, J. H.-R., Hedrick, P., Xia, Y., Allen, A., Ferreira, L. M. R., Strominger, J. L., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902566116 · Cited by 363
Liu, Q., Chiu, A., Wang, L., An, D., Li, W., Chen, E. Y., Zhang, Y., Pardo, Y., McDonough, S. P., Liu, L., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119640 · Cited by 120
Flagged first, then by citations
Research works printed but not linked: 41
- Mobasseri, 2020, Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis, Health Promot Perspect, 10, 98, 10.34172/hpp.2020.18 · DOI
- Foster, 2019, State of type 1 diabetes management and outcomes from the T1D exchange in 2016–2018, Diabetes Technol Ther, 21, 66, 10.1089/dia.2018.0384 · DOI · Paper page
- Shapiro, 2000, Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen, N Engl J Med, 343, 230, 10.1056/NEJM200007273430401 · DOI · Paper page
- Marfil-Garza, 2020, 116-OR: comparison of pancreas vs. islet transplantation outcomes from a large single center, Diabetes, 69
- Pepper, 2018, Clinical islet transplantation: is the future finally now?, Curr Opin Organ Transplant, 23, 428, 10.1097/MOT.0000000000000546 · DOI
- Shapiro, 2017, Clinical pancreatic islet transplantation, Nat Rev Endocrinol, 13, 268, 10.1038/nrendo.2016.178 · DOI
- Lemos, 2021, Survival after islet transplantation in subjects with type 1 diabetes: twenty-year follow-up, Diabetes Care, 44, e67, 10.2337/dc20-2458 · DOI
- Vantyghem, 2019, Ten-year outcome of islet alone or islet after kidney transplantation in type 1 diabetes: a prospective parallel-arm cohort study, Diabetes Care, 42, 2042, 10.2337/dc19-0401 · DOI · Paper page
- Marfil-Garza, 2021, Clinical islet transplantation: current progress and new frontiers, J Hepatobiliary Pancreat Sci, 28, 243, 10.1002/jhbp.891 · DOI
- Markmann, 2020, Phase 3 trial of human islet-after-kidney transplantation in type 1 diabetes, Am J Transplant, 21, 1477, 10.1111/ajt.16174 · DOI
- Zarinsefat, 2020, Chapter 34 - Islet vs pancreas transplantation in nonuremic patients with type 1 diabetes, Transplantation, bioengineering, and regeneration of the endocrine pancreas, 417, 10.1016/B978-0-12-814833-4.00034-4 · DOI
- Verhoeff, 2021, Inducible pluripotent stem cells as a potential cure for diabetes, Cells, 10, 278, 10.3390/cells10020278 · DOI
- Ryan, 2004, Risks and side effects of islet transplantation, Curr Diabetes Rep, 4, 304, 10.1007/s11892-004-0083-8 · DOI · Paper page
- Raval, 2020, 1093. Infectious complications after pancreatic islet transplantation, Open Forum Infect Dis, 7, S576-S576
- Naziruddin, 2018, Improved outcomes of islet autotransplant after total pancreatectomy by combined blockade of IL-1β and TNFα, Am J Transplant, 18, 2322, 10.1111/ajt.14961 · DOI
- Szempruch, 2019, Use of anti-inflammatory agents in clinical islet cell transplants: a qualitative systematic analysis, Islets, 11, 65, 10.1080/19382014.2019.1601543 · DOI
- Maffi, 2020, Targeting CXCR1/2 does not improve insulin secretion after pancreatic islet transplantation: a phase 3, double-blind, randomized, placebo-controlled trial in type 1 diabetes, Diabetes Care, 43, 710, 10.2337/dc19-1480 · DOI
- Zhang, 2003, Adeno-massociated virus-mediated IL-10 gene therapy inhibits diabetes recurrence in syngeneic islet cell transplantation of NOD mice, Diabetes, 52, 708, 10.2337/diabetes.52.3.708 · DOI
- Goudy, 2003, Systemic overexpression of IL-10 induces CD4+CD25+ cell populations in vivo and ameliorates type 1 diabetes in nonobese diabetic mice in a dose-dependent fashion, J Immunol, 171, 2270, 10.4049/jimmunol.171.5.2270 · DOI
- Xu, 2015, Interleukin-10 gene transfer into insulin-producing ( cells protects against diabetes in nonobese diabetic mice, Mol Med Rep, 12, 3881, 10.3892/mmr.2015.3809 · DOI
- Falcone, 2020, Role of the PD-1/PD-L1 dyad in the maintenance of pancreatic immune tolerance for prevention of type 1 diabetes, Front Endocrinol (Lausanne), 11, 569, 10.3389/fendo.2020.00569 · DOI
- Voltarelli, 2007, Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus, JAMA, 297, 1568, 10.1001/jama.297.14.1568 · DOI · Paper page
- Couri, 2009, C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus, JAMA, 301, 1573, 10.1001/jama.2009.470 · DOI · Paper page
- Zielinski, 2020, 66-LB: combined immunotherapy with T regulatory cells and anti-CD20 antibody prolongs survival of pancreatic islets in type 1 diabetes, Diabetes, 69
- Harden, 2020, Feasibility, long-term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients, Am J Transplant, 21, 1603, 10.1111/ajt.16395 · DOI
- Sawitzki, 2020, Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven nonrandomised, single-arm, phase 1/2A trials, Lancet, 395, 1627, 10.1016/S0140-6736(20)30167-7 · DOI
- Marfil-Garza, 2021, Progress in translational regulatory t cell therapies for type 1 diabetes and islet transplantation, Endocr Rev, 42, 198, 10.1210/endrev/bnaa028 · DOI
- Rezania, 2014, Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells, Nat Biotechnol, 32, 1121, 10.1038/nbt.3033 · DOI · Paper page
- Hogrebe, 2020, Targeting the cytoskeleton to direct pancreatic differentiation of human pluripotent stem cells, Nat Biotechnol, 38, 460, 10.1038/s41587-020-0430-6 · DOI · Paper page
- Pepper, 2019, Posttransplant characterization of long-term functional hESC-derived pancreatic endoderm grafts, Diabetes, 68, 953, 10.2337/db18-0788 · DOI
- Marfil-Garza, 2020, Current state and evidence of cellular encapsulation strategies in type 1 diabetes, Compr Physiol, 10, 839, 10.1002/j.2040-4603.2020.tb00139.x · DOI
- Bose, 2020, A retrievable implant for the long-term encapsulation and survival of therapeutic xenogeneic cells, Nat Biomed Eng, 4, 814, 10.1038/s41551-020-0538-5 · DOI
- Vegas, 2016, Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice, Nat Med, 22, 306, 10.1038/nm.4030 · DOI · Paper page
- Yu, 2020, Islet transplantation in the subcutaneous space achieves long-term euglycaemia in preclinical models of type 1 diabetes, Nat Metab, 2, 1013, 10.1038/s42255-020-0269-7 · DOI
- Takahashi, 2007, Induction of pluripotent stem cells from adult human fibroblasts by defined factors, Cell, 131, 861, 10.1016/j.cell.2007.11.019 · DOI · Paper page
- Sui, 2018, Pancreatic beta cell differentiation from human pluripotent stem cells, Curr Protoc Hum Genet, 99, e68, 10.1002/cphg.68 · DOI
- Rosado-Olivieri, 2019, YAP inhibition enhances the differentiation of functional stem cell-derived insulin-producing ( cells, Nat Commun, 10, 1464, 10.1038/s41467-019-09404-6 · DOI
- Shi, 2020, Generation of hypoimmunogenic human pluripotent stem cells via expression of membrane-bound and secreted (2m-HLA-G fusion proteins, Stem Cells, 38, 1423, 10.1002/stem.3269 · DOI
- Witkowski, 2020, The demise of islet allotransplantation in the United States: a call for an urgent regulatory update, Am J Transplant, 21, 1365, 10.1111/ajt.16397 · DOI
- Wojtusciszyn, 2019, Indications for islet or pancreatic transplantation: statement of the TREPID Working Group on behalf of the Société francophone du diabète (SFD), Société francaise d’endocrinologie (SFE), Société francophone de transplantation (SFT) and Société française de néphrologie - dialyse - transplantation (SFNDT), Diabetes Metab, 45, 224, 10.1016/j.diabet.2018.07.006 · DOI
- Witkowski, 2021, Regulatory updates are needed to prevent the commercialization of islet transplantation in the United States, Am J Transplant
Cited by
Sorted by citations
Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes
Hogrebe, N. J., Ishahak, M., & Millman, J. R. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.04.002 · Cited by 210
Characterization of stem-cell-derived islets during differentiation and after implantation
Cuesta-Gomez, N., Verhoeff, K., Jasra, I. T., Pawlick, R., Dadheech, N., & Shapiro, A. M. J. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111238 · Cited by 41
Self-citationVerhoeff, K. K., Marfil‐Garza, B. A., Sandha, G. S., Cooper, D. K. C., Dajani, K. Z., Bigam, D. L., Anderson, B. L., Kin, T., Lam, A. P., O’Gorman, D., et al. (2022) · Transplantation · doi:10.1097/tp.0000000000004180 · Cited by 26
Self-citationVerhoeff, K., Cuesta-Gomez, N., Maghera, J., Dadheech, N., Pawlick, R., Smith, N., O’Gorman, D., Razavy, H., Marfil-Garza, B., Young, L. G., et al. (2025) · Transplantation · doi:10.1097/tp.0000000000005108 · Cited by 16
Self-citationOptimizing Generation of Stem Cell-Derived Islet Cells
Verhoeff, K. K., Cuesta‐Gomez, N., Jasra, I. T., Marfil‐Garza, B. A., Dadheech, N., & Shapiro, A. M. J. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10391-3 · Cited by 11
“Efficiently and safely differentiating SCs into functional islets could provide an unlimited supply of hypo- or non-immunogenic cells for β-cell replacement therapies [67, 137, 138].”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Verhoeff, K., Marfil-Garza, B. A., & Shapiro, A. M. J.
- Affiliations
- University of Alberta (CA)
- Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
- Corresponding author
- Shapiro, A.M. James
- ORCID
- Verhoeff, Kevin
- Venue
- Current Opinion in Organ Transplantation
- Published
- 2021-06-18
- Volume
- 26
- Issue
- 4
- Pages
- 397-404
- ISSN
- 1087-2418 (ISSN-L)
- 1531-7013
- OpenAlex
- W3174574231
- Cited by
- 29
- References
- 0
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 6 · 2023: 9 · 2022: 5
- FWCI
- 1.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Organ Transplantation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- islet transplantation, type 1 diabetes, glycemic control, hypoglycemia, insulin independence, chronic immunosuppression, diabetes complications
- MeSH terms
- Diabetes Mellitus, Type 1, Humans, Hypoglycemia, Immunosuppression Therapy, Insulin, Islets of Langerhans Transplantation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
